Andere Sprachen Tango Therapeutics, Inc.

Aktien

A3CWX9

US87583X1090

TNGX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 22.04.2024			% 5 Tage	% 1. Jan.
7,31 ^USD	0,00 %		-0,14 %	-26,16 %

04.04.	TANGO THERAPEUTICS, INC. : Von Cantor Fitzgerald zum Kauf angehoben	ZM
21.03.	TANGO THERAPEUTICS, INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

British billionaire Joe Lewis fined $5 million by US judge for insider trading	04.04.
Multibillionaire Joe Lewis to face US sentencing for insider trading	04.04.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.04.
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	18.03.
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18.03.
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	18.03.
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index	18.03.
Tango Therapeutics to Participate in Upcoming Investor Conferences	06.03.
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	05.03.
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	31.01.
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	24.01.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05.01.
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04.01.
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04.01.
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348	03.01.
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	03.01.
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers	03.01.
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	13.11.
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tango Therapeutics, Inc.

Aktien

A3CWX9

US87583X1090

TNGX

Andere Sprachen

Filter